

Strategies to Advance Nanomedicines in Oncology

Christine Allen, Ph. D.

Professor &
GSK Chair in Pharmaceutics and Drug Delivery
Leslie Dan Faculty of Pharmacy
University of Toronto

Date : **Lundi, 18 août 2014**

Heure : **8 h 30**

Lieu : Salle S1-125
Pavillon Jean-Coutu

À l'invitation du professeur Grégoire Leclair

Christine Allen is a Professor and the GSK Chair for Pharmaceutics and Drug Delivery in the Leslie Dan Faculty of Pharmacy at the University of Toronto. She is also currently serving as the interim Associate Dean for Graduate Education. Her research is focused on the rational design and development of new materials and technologies for the delivery of drugs and contrast agents (Lab Website: <http://phm.utoronto.ca/~allen/>). Allen completed her doctoral research in the Department of Chemistry at McGill University and post-doctoral research in the Department of Advanced Therapeutics at the B.C. Cancer Agency. She joined University of Toronto in 2002, from Celator Pharmaceuticals Inc. (Vancouver, B.C.) where she had worked as a scientist and Assistant Director of materials research. She has over 90 publications, numerous patent applications, and nine book chapters on both lipid and polymer-based delivery systems. She has served on several peer review panels for granting agencies including CIHR (2004, 2005-2009, 2011), NCIC (2005, 2006) and NIH (2006, 2008, 2011 - 2017). She was awarded a CIHR-Rx&D Career Award (2004-2009) for her research on the design and development of technologies for cancer treatment. She has also received the Association of Faculties of Pharmacy of Canada/AstraZeneca New Investigator Research Award, the Canadian Society Pharmaceutical Science/GlaxoSmithKline Early Career Award, an Innovation Award from the Ontario Research Commercialization Program and the Jorge Heller Controlled Release Society (CRS) Best Paper Award in 2011. She is an Associate Editor for the ACS journal Molecular Pharmaceutics and involved in numerous scientific societies including as an elected member on the board of directors of CRS.